Harris A. Gelbard

Tumor necrosis factor-alpha in normal and diseased brain: Conflicting effects via intraneuronal receptor crosstalk?

Reduced expression of glutamate transporter EAAT2 and impaired glutamate transport in human primary astrocytes exposed to HIV-1 or gp120.

Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis.

Synapses and Sisyphus: life without paraplegin.

Effects of human immunodeficiency virus type 1 on astrocyte gene expression and function: potential role in neuropathogenesis.

Immunohistochemical assessment of fractalkine, inflammatory cells, and human herpesvirus 7 in human salivary glands.

Activation of adenosine A2A receptor protects sympathetic neurons against nerve growth factor withdrawal.

Antioxidants are required during the early critical period, but not later, for neuronal survival.

Neuroprotective strategies for HIV-1 associated dementia.

HIV-1 transactivator of transcription protein induces mitochondrial hyperpolarization and synaptic stress leading to apoptosis.

Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis.

Synaptic activity becomes excitotoxic in neurons exposed to elevated levels of platelet-activating factor.

Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation.

Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase-3beta to antagonize nuclear factor-kappaB survival pathway in neurons.

HIV-1 trans activator of transcription protein elicits mitochondrial hyperpolarization and respiratory deficit, with dysregulation of complex IV and nicotinamide adenine dinucleotide homeostasis in cortical neurons.

Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia.

Protecting the synapse: evidence for a rational strategy to treat HIV-1 associated neurologic disease.

Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS.

The phospholipid mediator platelet-activating factor mediates striatal synaptic facilitation.

HIV-1 Tat activates neuronal ryanodine receptors with rapid induction of the unfolded protein response and mitochondrial hyperpolarization.

Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment.

Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders.

Neuroprotective activities of CEP-1347 in models of neuroAIDS.

Relationships between markers of vascular dysfunction and neurodevelopmental outcomes in perinatally HIV-infected youth.

Two-photon NADH imaging exposes boundaries of oxygen diffusion in cortical vascular supply regions.

Rebuilding synaptic architecture in HIV-1 associated neurocognitive disease: a therapeutic strategy based on modulation of mixed lineage kinase.

Human immunodeficiency virus-1 Tat activates calpain proteases via the ryanodine receptor to enhance surface dopamine transporter levels and increase transporter-specific uptake and Vmax.

Ablation of mixed lineage kinase 3 (Mlk3) does not inhibit ototoxicity induced by acoustic trauma or aminoglycoside exposure.

Loss of neuronal integrity during progressive HIV-1 infection of humanized mice.

Mitochondrial membrane potential probes and the proton gradient: a practical usage guide.

HIV-1 Tat-induced microgliosis and synaptic damage via interactions between peripheral and central myeloid cells.